Di Marco, Vito

Publishing since 1985 (Dinosaur)

Has published 76 publications in 26 years

Number of publications published per year by Di Marco, Vito. (Source : PubMed)

Distribution of publications types for Di Marco, Vito. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Cabibi D, Tarantino G, Barbaria F, Campione M, Craxì A, Di Marco V. Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases.  Dig Liver Dis  2010  
•  Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, Licata G, Porcasi R, Marchesini G, Craxí A. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.  Hepatology  2009  
•  Calvaruso V, Cammà C, Di Marco V, Maimone S, Bronte F, Enea M, Dardanoni V, Manousou P, Pleguezuelo M, Xirouchakis E, Attanasio M, Dusheiko G, Burroughs AK, Craxì A. Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy.  J. Viral Hepat.  2009  
•  Petta S, Cammà C, DI Marco V, Calvaruso V, Enea M, Bronte F, Butera G, Cabibi D, Craxì A. Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis.  Aliment. Pharmacol. Ther.  2009;30;6  
•  Ferraro D, Pizzillo P, Di Marco V, Vultaggio A, Iannitto E, Venezia G, Craxì A, Di Stefano R. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?  Liver Int.  2009;29;8  
•  Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.  Hepatology  2009;49;6  
•  Licata A, Nebbia ME, Cabibbo G, Iacono GL, Barbaria F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxì A, Cammà C. Hyperferritinemia is a risk factor for steatosis in chronic liver disease.  World J. Gastroenterol.  2009;15;17  
•  Di Marco V, Craxì A. Chronic hepatitis B: who to treat and which choice of treatment?  Expert Rev Anti Infect Ther  2009;7;3  
•  Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, Squadrito G, Di Marco V, Craxì A, Raimondo G. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.  Antivir. Ther. (Lond.)  2009;14;5  
•  Petta S, Cammà C, Di Marco V, Cabibi D, Ciminnisi S, Caldarella R, Licata A, Massenti MF, Marchesini G, Craxì A. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.  Antivir. Ther. (Lond.)  2009;14;5  

[ See timeline ] [ See all publications ]